Multiple Sclerosis and fungi – is there a link?
This week on The Mould Show we're going to be looking at the gut microbiome and in particular, some emerging research that is showing that the diversity of microorganisms found in the gut may be linked to different immune responses and may even affect the pathogenesis of conditions like multiple sclerosis, MS.
I'll be reviewing two of the dominant papers in the MS literature around gut microflora and looking at this concept of species diversity. In these papers, the scientists looked at the number of different microorganisms between healthy controls and MS patients.
Multiple sclerosis is a neuro-inflammatory autoimmune disease known to affect two and a half million people worldwide with most patients experiencing what is termed relapsing-remitting Multiple Sclerosis which as the name suggests shows periods of stasis punctuated with symptoms but overwhelmingly moves towards more frequent symptoms as the disease progresses. There are currently no known treatments for MS. However, there is an abundant literature showing that healthy lifestyle factors such as no current smoking, a healthy diet regular exercise, and maintaining a low body mass index all help reduce symptoms.
The two papers we're looking at today ask the question: Are there some fungi that can be measured in the gut that are correlated with MS and healthy controls? Essentially, what is the role that microbiology plays in MS?.
These two papers strongly suggest that bacterial and fungal diversity is indeed connected and can differentiate healthy controls from MS patients. This research is exciting because it offers the opportunity not only for individualized testing as a risk predictor but also the opportunity for individualized dietary modifications to be made to change the composition of the gut microflora.
Both papers determined that fungi like Candida, Epicoccum, Malassezia and Saccharomyces all seem to show statistical relationships that could be a value to predict or at least classify individuals into different risk categories.
Interestingly, when we drill into the literature and look at the species diversity for Saccharomyces which is a typical yeast found in breads and grains there is another set of literature that has looked at the gut microbiota and the day 28-day mortality for critically ill patients admitted to hospital. Of course, many of the underlying reasons for hospital admission include chronic lung disease, chronic heart disease, immunosuppression, active cancer, and acute kidney injury. Nevertheless, when sampling was performed, they found clear evidence that species diversity in the gut was predictive for which patients survived versus those that died?
So, what to make of these facts? Well, there is an opportunity to look at what readily available compounds might be used nutritionally or therapeutically, to mitigate, delay, or reverse these diseases?
One of the compounds being actively researched is called Astaxanthin and is commonly found in shellfish and lobsters and green micro algae. It’s been shown to not only possess anti-microbial or antibiotic type activity but there is emerging research it can be used for a range of neurodegenerative diseases, including stroke, multiple sclerosis, Alzheimer’s, and even conditions like chronic fatigue syndrome. This research into the use of astaxanthin suggests that even if it cannot be used as a topical anti-microbial (due to high dosage), it may exert its beneficial effect by altering the composition of the gut microflora at a lower dosage. Other elegant research has looked at how astaxanthin has been able to protect the myelin sheath in Multiple Sclerosis models in rats. This research strongly suggests that astaxanthin exerts its effect because they help reduce inflammation and oxidative stress.
We can only hope that more research into the therapeutic effects of natural compounds like astaxanthin may lead towards the widespread use of targeted dietary modifications. This could result in near-term benefits for a range of people suffering from immune-mediated neurodegenerative conditions and that’s a win for all.
WATCH THE LIVESTREAM:
REFERENCES:
Yadav, M., Ali, S., Shrode, R. L., Shahi, S. K., Jensen, S. N., Hoang, J., Cassidy, S., Olalde, H., Guseva, N., Paullus, M., Cherwin, C., Wang, K., Cho, T., Kamholz, J., & Mangalam, A. K. (2022). Multiple sclerosis patients have an altered gut mycobiome and increased fungal to bacterial richness. PloS one, 17(4), e0264556. https://doi.org/10.1371/journal.pone.0264556
Shah, S., Locca, A., Dorsett, Y., Cantoni, C., Ghezzi, L., Lin, Q., Bokoliya, S., Panier, H., Suther, C., Gormley, M., Liu, Y., Evans, E., Mikesell, R., Obert, K., Salter, A., Cross, A., Tarr, P., Lovett-Racke, A., Piccio, L. and Zhou, Y., 2021. Alterations of the gut mycobiome in patients with MS. EBioMedicine, 71, p.103557. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00350-9/fulltext
Prevel R, Enaud R, Orieux A, Camino A, Berger P, Boyer A, Delhaes L, Gruson D. Gut bacteriobiota and mycobiota are both associated with Day-28 mortality among critically ill patients. Crit Care. 2022 Apr 13;26(1):105. doi: 10.1186/s13054-022-03980-8. PMID: 35418098; PMCID: PMC9007252.
Fadhel M, Patel S, Liu E, Levitt M, Asif A. Saccharomyces cerevisiae fungemia in a critically ill patient with acute cholangitis and long term probiotic use. Med Mycol Case Rep. 2018 Nov 12;23:23-25. doi: 10.1016/j.mmcr.2018.11.003. PMID: 30505677; PMCID: PMC6251791.
Veronese N, Yang L, Piccio L, Smith L, Firth J, Marx W, Giannelli G, Caruso MG, Cisternino AM, Notarnicola M, Donghia R, Barbagallo M, Fontana L. Adherence to a healthy lifestyle and multiple sclerosis: a case-control study from the UK Biobank. Nutr Neurosci. 2022 Jun;25(6):1231-1239. doi: 10.1080/1028415X.2020.1846357. Epub 2020 Dec 9. PMID: 33297884. https://doi.org/10.1080/1028415X.2020.1846357
Bidaran S, Ahmadi AR, Yaghmaei P, Sanati MH, Ebrahim-Habibi A. Astaxanthin effectiveness in preventing multiple sclerosis in animal model. Bratisl Lek Listy. 2018;119(3):160-166. doi: 10.4149/BLL_2018_031. PMID: 29536745. https://pubmed.ncbi.nlm.nih.gov/29536745/
Alugoju P, Krishna Swamy VKD, Anthikapalli NVA, Tencomnao T. Health benefits of astaxanthin against age-related diseases of multiple organs: A comprehensive review. Crit Rev Food Sci Nutr. 2022 Jun 16:1-66. doi: 10.1080/10408398.2022.2084600. Epub ahead of print. PMID: 35708049. https://pubmed.ncbi.nlm.nih.gov/35708049/
Karpiński TM, Ożarowski M, Alam R, Łochyńska M, Stasiewicz M. What Do We Know about Antimicrobial Activity of Astaxanthin and Fucoxanthin? Mar Drugs. 2021 Dec 29;20(1):36. doi: 10.3390/md20010036. PMID: 35049891; PMCID: PMC8778043. https://pubmed.ncbi.nlm.nih.gov/35049891/
Willis, A., 2019. Rarefaction, Alpha Diversity, and Statistics. Frontiers in Microbiology, 10. https://doi.org/10.3389/fmicb.2019.02407
Lotfi, A., Soleimani, M., & Ghasemi, N. (2021). Astaxanthin Reduces Demyelination and Oligodendrocytes Death in A Rat Model of Multiple Sclerosis. Cell journal, 22(4), 565–571. https://doi.org/10.22074/cellj.2021.6999 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211289/
Sztretye, M., Dienes, B., Gönczi, M., Czirják, T., Csernoch, L., Dux, L., Szentesi, P., & Keller-Pintér, A. (2019). Astaxanthin: A Potential Mitochondrial-Targeted Antioxidant Treatment in Diseases and with Aging. Oxidative medicine and cellular longevity, 2019, 3849692. https://doi.org/10.1155/2019/3849692 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878783/
